BLA 761143 · Horizon Therapeutics Ireland
Tepezza
Teprotumumab-Trbw · Injection · Insulin-like Growth Factor-1 Receptor Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jan 21, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
4 Phase 3, 5 recruiting
FAERS reports
5,951
2,588 serious, 41 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 28, 2026.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. TEPEZZA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration ( 1 )
Mechanism: Teprotumumab-trbw's mechanism of action in patients with Thyroid Eye Disease has not been fully characterized. Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 21, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- TEPEZZA · TEPROTUMUMAB-TRBW 500MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Teprotumumab" as an intervention, any sponsor and status, largest first.
- TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement StudyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05002998 · 313 participants · Start Sep 16, 2021 · Primary completion Dec 19, 2025
Drug: Teprotumumab; Placebo · For: Thyroid Eye Disease
Sites: Beverly Hills, California; Los Angeles, California; Palo Alto, California · 28 sites in all
- A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseasePivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07113262 · 111 participants (planned) · Start Sep 10, 2025 · Primary completion Dec 31, 2026
Drug: IBI311; Placebo · For: Thyroid Eye Disease
Sites: Shenyang, China
Shanghai Changzheng HospitalAcademic, hospital or other
NCT07152366 · 96 participants (planned) · Start Apr 15, 2025 · Primary completion May 31, 2027
Drug: IBI311; Glucocorticoids · For: Thyroid Associated Ophthalmopathies
Sites: Shanghai, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07265258 · 92 participants (planned) · Start Jul 30, 2026 · Primary completion Jun 30, 2028
Drug: Teprotumumab N01; Methylprednisolone · For: Thyroid Eye Disease
Sites: Shanghai, China
- A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye DiseasePivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06248619 · 89 participants · Start Jul 5, 2024 · Primary completion Dec 23, 2025
Drug: Teprotumumab · For: Thyroid Eye Disease
Sites: Tucson, Arizona; Orland Park, Illinois; Ann Arbor, Michigan · 38 sites in all
AmgenAmgen (AMGN)
NCT01868997 · 88 participants · Start Jul 2013 · Primary completion Mar 2016
Drug: teprotumumab; normal saline · For: Thyroid Associated Ophthalmopathies; Thyroid-Associated Ophthalmopathy
Sites: Los Angeles, California; Aurora, Colorado; Atlanta, Georgia · 15 sites in all
- Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical StudyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03298867 · 83 participants · Start Oct 4, 2017 · Primary completion Feb 13, 2019
Drug: Teprotumumab · For: Thyroid Eye Disease; Graves' Orbitopathy
Sites: Beverly Hills, California; Los Angeles, California; Coral Gables, Florida · 14 sites in all
Shanghai Changzheng HospitalAcademic, hospital or other
NCT07152340 · 64 participants (planned) · Start Apr 10, 2025 · Primary completion Apr 30, 2027
Drug: IBI311; Glucocorticoids · For: Thyroid Associated Ophthalmopathies
Sites: Changhua, China; Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- muscle spasms1,156
- fatigue822
- tinnitus627
- hypoacusis504
- headache499
- diarrhoea462
- blood glucose increased458
- nausea453
- alopecia441
- endocrine ophthalmopathy375
- pain360
- anxiety350
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 475 |
| 2021 | 692 |
| 2022 | 727 |
| 2023 | 732 |
| 2024 | 1,869 |
| 2025 | 702 |
| 2026 | 754 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tepezza (Teprotumumab-Trbw)
2024 spending
$152M
Beneficiaries
515
2,708 claims
Per beneficiary
$294,974
$14,094.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $42,287,713 |
| 2021 | $61,244,125 |
| 2022 | $90,892,963 |
| 2023 | $129,065,494 |
| 2024 | $151,911,672 |
Part B: Tepezza (Teprotumumab-Trbw) · HCPCS J3241
2024 spending
$246M
Beneficiaries
962
5,046 claims
Per beneficiary
$256,201
2024 ASP limit $335.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $65,401,279 |
| 2021 | $302,693,259 |
| 2022 | $308,126,858 |
| 2023 | $273,505,773 |
| 2024 | $246,465,795 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS, Kahaly GJ, Patel A, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ, Kahaly GJ, Ezra DG, et al. · N Engl J Med 2017 · Multicenter Study, Randomized Controlled Trial
- Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS, Kahaly GJ, Ugradar S, et al. · Ophthalmology 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS, Couch S, Wester ST, et al. · J Clin Endocrinol Metab 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
Kahaly GJ, Subramanian PS, Conrad E, et al. · Thyroid 2024 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis.
Huang W, Ou X, Lin S, et al. · Endocr Pract 2025 · Systematic Review, Meta-Analysis
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.